We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Lime Global

Status: Extended

Jul 12th 2021 - Aug 11th 2021

Lime Global is a UK-based company dedicated to becoming the most customer-focused provider of health cover. Lime argues that conventional health insurance is too expensive and overly complicated. It intends to make health insurance affordable allowing customers to buy the top-ups they want without consulting advisers or filling long questionnaires. Lime Global claims to provide customers with a cancer cover providing a lump sum and support following diagnosis, access to 'Rapid Diagnostics' to avail private diagnostic tests, and an online platform where customers and employers can book and pay for clinical services. Lime Global aspires to become a contender in the UK private healthcare market set to grow more than £8 billion. The company points out that it has secured 5 star Trustpilot reviews over the last year with zero complaints to date. They intend to use the investment to support their expansion into Small and Medium Enterprises (SMEs), mental health modules and e-pharmacies, scale customer acquisition, and support the next stage of its growth in late 2021 and early 2022.

read more read less

Lime Global Rating Review

Pitch rating powered by CROWDRATING

Rated on 06/08/2021

Pitch Rated

44%

Insufficient Data

Management

74%

Product

59%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £24,077,044
    pre-money valuation

    1.63%
    equity available

    209
    investors

    £2,272
    pledge per investor

    09666467
    company number

    Active
    company status

    01/07/2015
    incorporated 9 years

    Previous Funding rounds
    25 Apr 24 Seedrs £474,838 / 119% 44.33%
    News

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 74%

Skills 73%
The 'Lime Global' management team comprises skilled professionals whose published LinkedIn profiles include management, marketing, and communication expertise. They have an experienced team in place that consists of a Founder/CEO, Head of Technology, Head of Communication, and Strategic Partnerships. The Founder/CEO is competent in strategic planning, public speaking, risk management, and executive management. The Head of Technology is skilled in analytics, information technology, customer experience, and time management. The Head of Strategic Partnerships and Head of Communications can build brand awareness by direct marketing, sales management, public relation, relationship management, and corporate communication. It was noted that there is no dedicated finance head in the team at this stage of fundraising.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £24,077,044
    pre-money valuation

    1.63%
    equity available

    209
    investors

    £2,272
    pledge per investor

    09666467
    company number

    Active
    company status

    01/07/2015
    incorporated 9 years

    Previous Funding rounds
    26 Apr 24 Seedrs £474,838 / 119% 44.33%
    News
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph